Tandem Diabetes Care Announces NEJM Publication of Pediatric Study Demonstrating Increased Time-In-Range using the t:slim X2 Insulin Pump with Control-IQ Technology – read this article along with other careers information, tips and advice on BioSpace
After its Biologics License Application was rejected by the FDA, BrainStorm’s Phase III data suggest its amyotrophic lateral sclerosis candidate significantly lowers neurofilament light chain…
The majority of ALS patients are excluded from clinical trials. Experts say using biomarkers and stratifying trial populations can expand eligibility and provide additional scientific…
Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.
Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma – read…
Grail, the blood testing company, explores the potential of its commercial blood test, Galleri, in detecting cancer symptoms.
Preliminary trial results show the GSK five-in-one meningitis vaccine is immunologically effective against the most common strains, as the FDA decision date for Pfizer’s candidate…
The regulator in a Complete Response Letter rejected ImmunityBio’s bladder cancer hopeful due to deficiencies with the company’s third-party contract manufacturer.
Cancer vaccines enjoyed a moment in the spotlight this week as Moderna, Merck, Nykode Therapeutics and Transgene shared promising updates at AACR and beyond.
At the World Vaccine Congress, antimicrobial resistance as a global health crisis grabbed top billing. AMR is a global health crisis that puts the highest…
HUTCHMED has completed the rolling submission of its New Drug Application to the FDA for fruquintinib, its candidate for refractor metastatic colorectal cancer.
